Bayer Partners with NVIDIA-Backed AI Drug Discovery Firm Iambic Therapeutics
Today,Bayer and Iambic Therapeutics Announce Drug Discovery Collaboration, Leveraging Iambic’s AI-Driven Platform for Novel Drug Discovery
This collaboration will leverage Iambic’s AI-driven drug discovery platform, including its flagship AI technologies Enchant and NeuralPLexer, to identify novel druggable sites and differentiated molecules for targets that are traditionally difficult to drug, thereby enhancing Bayer’s early-stage pipeline.
Iambic Therapeutics was founded inIn early 2020,Headquartered in San Diego, United States, the company was founded by two chemistry professors.
In June 2024, the company completed a $150 millionSeries B financing, with the total cumulative funding reaching**$200 million, with investors including**NVIDIA, the Global AI Hegemon.
Iambic Therapeutics has built a renownedForInsightAn R&D platform integrating artificial intelligence and physics to create more reliable and accurate models for deeper exploration of the chemical domain; the platform is primarily divided into four components.
NeuralPLexer: Predicting protein–ligand complexes, including binding-induced conformational responses, to reveal novel mechanisms of action, allosteric sites, and cryptic pockets
OrbNet: AI-Accelerated Quantum Chemistry for Calculating Protein-Ligand Binding Energies
PropANE: A Lead Compound Parameter Optimization Model Capable of Training on Dozens of Drug Properties
Magnet: Generate Molecular Designs
The company's molecular design software, Magnet, can design in a single step1024 molecules, and integrated with wet labs to refine molecular predictions based on test results,A design-manufacture-test cycle typically takes 9 days.
Iambic'sThe generative model NeuralPLexer is designed forPrediction of protein-ligand complexes is also included in this collaboration.
This February,
Takeda Pharmaceutical
Announcement and AI Pharmaceutical Company
Iambic Therapeutics
Sign a multi-year agreement.
The two parties will advance the development of select small-molecule programs, starting in the fields of oncology, gastroenterology, and inflammation. The potential total value of this collaboration is up to$1.7 billion。
In addition to Takeda, Iambic also collaborates with companies including Revolution Medicines, Jazz Pharmaceuticals, and Lundbeck.
—The End—
Recommended Reading
Summary
Bayer has announced a drug discovery collaboration with Iambic Therapeutics, leveraging Iambic's AI-driven Insight platform—including flagship technologies Enchant and NeuralPLexer—to identify novel binding sites and differentiated molecules against historically undruggable targets. Founded in early 2020 by two chemistry professors and headquartered in San Diego, Iambic has raised 200milliontodate,includinga150 million Series B in June 2024 with investment from NVIDIA. The company’s platform integrates AI and physics-based models across four core components: NeuralPLexer for protein-ligand complex prediction, OrbNet for quantum chemistry acceleration, PropANE for lead optimization, and Magnet for generative molecular design capable of producing 1,024 molecules per cycle. Iambic has also secured major partnerships with Takeda (up to $1.7 billion), Revolution Medicines, Jazz Pharmaceuticals, and Lundbeck.